Cargando…
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
BACKGROUND: Irinotecan is a camptothecin analogue currently used in clinical practice to treat advanced colorectal cancer. However, acquired resistance mediated by the drug efflux pump ABCG2 is a recognized problem. We reported on a novel camptothecin analogue, FL118, which shows anticancer activity...
Autores principales: | Westover, David, Ling, Xiang, Lam, Hong, Welch, Jacob, Jin, Chunyang, Gongora, Celine, Del Rio, Maguy, Wani, Mansukh, Li, Fengzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427926/ https://www.ncbi.nlm.nih.gov/pubmed/25928015 http://dx.doi.org/10.1186/s12943-015-0362-9 |
Ejemplares similares
-
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015) -
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
por: Ling, Xiang, et al.
Publicado: (2018) -
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017) -
An ABCG-Type Transporter Facilitates ABA Influx and Regulates Camptothecin Biosynthesis in Camptotheca acuminata
por: Wang, Yanyan, et al.
Publicado: (2022) -
ABCG2 Gene and ABCG2 Protein Expression in Colorectal Cancer—In Silico and Wet Analysis
por: Sałagacka-Kubiak, Aleksandra, et al.
Publicado: (2023)